Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 5/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27364556 | 0.86 | IRAK4 (0.47) | ESR2ESR1GSK3BDYRK1A | |
| SCHEMBL17430152 | 0.85 | MAPT (0.49) | GSK3BDYRK1AMAPTBCL2MAP4K4 | |
| SCHEMBL12403311 | 0.85 | GSK3B (0.47) | GSK3BDYRK1AMAPTBCL2GRIN2B | |
| SCHEMBL5958787 | 0.80 | MAPT (0.47) | GSK3BDYRK1AMAPTBCL2CDK9 | |
| SCHEMBL1289516 | 0.79 | ESR1 (0.53) | ESR2ESR1NQO2 | |
| SCHEMBL851343 | 0.78 | DEGS1 (0.56) | GSK3BDYRK1ADEGS1GRIN2B | |
| SCHEMBL15096755 | 0.77 | ESR1 (0.51) | ESR2ESR1NQO2 | |
| SCHEMBL17430158 | 0.77 | ESR2 (0.48) | ESR2ESR1MAPTAPPMAOB | |
| SCHEMBL17430154 | 0.76 | MAPT (0.49) | GSK3BDYRK1AMAPTBCL2CDK9 | |
| SCHEMBL17430151 | 0.76 | MAPT (0.55) | GSK3BDYRK1AMAPTBCL2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9452985-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-9452985-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20160271278-A1 | TAU IMAGING PROBE | GE HEALTHCARE LTD (GB) | 2016-09-22 | — | — | US | disclosed |
| US-20160271278-A1 | TAU IMAGING PROBE | GE HEALTHCARE LTD (GB) | 2016-09-22 | — | — | US | disclosed |
| US-9249101-B2 | Tau imaging probe | CLINO LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-9249101-B2 | Tau imaging probe | CLINO LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20160008494-A1 | TAU IMAGING PROBE | GE HEALTHCARE LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20160008494-A1 | TAU IMAGING PROBE | GE HEALTHCARE LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2012057312-A1 | TAU IMAGING PROBE | クリノ株式会社 (JP) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008494-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | ESR2 1840/4885ESR1 2977/4885GSK3B 65/4885 |
| US-20160271278-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | ESR2 1840/4885ESR1 2977/4885GSK3B 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.